Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Core Viewpoint - Quoin Pharmaceuticals has announced highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome study, showing significant improvement in patients' disease state after two weeks of treatment with QRX003, a topical lotion [1][4]. Group 1: Clinical Data and Results - Dramatic improvement in the patient's disease state was observed, with clear visual evidence of skin healing after just two weeks of whole-body application of QRX003 [1]. - Both key clinical endpoints, Investigator's Global Assessment (IGA) and Pruritus, showed highly significant clinical improvements from baseline after two weeks of treatment [2]. - The patient's IGA score improved from 7 at baseline to between 1-2 after treatment, indicating almost complete elimination of the visual effects of the disease [4]. - The Pruritus score decreased from 5 to 1, reflecting a significant reduction in itch severity [2][4]. - The patient has discontinued previously required medications, including antihistamines, glucocorticoids, and antivirals, and has not needed antibiotics since treatment began [3][4]. Group 2: Patient Impact - The patient is now experiencing zero nightly sleep disturbances for the first time in her life, further indicating the potential efficacy of QRX003 [3][4]. - The results suggest that QRX003 may directly target the root cause of Netherton Syndrome, providing patients with a chance to live free from the disease's severe impacts [4]. Group 3: Company Overview and Future Plans - Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, including Netherton Syndrome [8]. - The company plans to expand the study to include additional pediatric subjects in other countries, aiming to further validate the encouraging results observed [4].